Amgen Ventures Invests in TileDB to Advance Their Universal Database

TileDB, Inc., a pioneering database company, has received a strategic investment from Amgen Ventures, supplemented by previous investments from Lockheed Martin Ventures and NTT Docomo Ventures, to enhance the development of its universal database. TileDB addresses the fragmented and costly data workflows in life sciences by offering a platform that uses multi-dimensional arrays to store and analyze diverse data types on any backend, enabling seamless integration and advanced analytics. This approach allows pharmaceutical companies to unify various data types such as images, tables, and genomic data, facilitating secure, scalable, and interoperable analytics workflows. TileDB's offerings include the open-source TileDB Embedded storage engine and TileDB Cloud, which provides secure governance, scalable compute, and data sharing capabilities. Stavros Papadopoulos, the CEO and original creator of TileDB, emphasizes the platform's potential to accelerate reproducible science through its innovative approach to data management and analysis. Amgen Ventures, a corporate fund established in 2004, invests in emerging technologies to advance healthcare solutions and has a history of strategic investments in human therapeutics and drug discovery innovations.